Gastro Medical News about Liver Cirrhosis

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

New Ovarian Cancer Test Guides Surgical Decisions

Roberta Buell, MBA
2010 Part D May Hurt Low Income Patients

Dorothy J. Schirf, MD

Technology Advances

Upcoming Cryo-Imaging Confers Single-Cell Resolution

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis
Scandinavian Journal of Gastroenterology, 11/06/09

Miyakawa K et al. – Continuously high ALAT levels for three successive years following the diagnosis of LC can be predictive of a very high incidence of HCC in Child A HCV–LC patients. Prospective trials using therapeutic approaches aimed at decreasing ALAT levels are necessary in order to confirm a positive impact of ALAT reduction on the incidence of HCC in patients with HCV–LC.

<< Previous
Long-term outcomes of endoscopic submucosal dissection in gastric...

Next >>
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma:...